[go: up one dir, main page]

WO1997017085A3 - Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison - Google Patents

Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison Download PDF

Info

Publication number
WO1997017085A3
WO1997017085A3 PCT/US1996/017860 US9617860W WO9717085A3 WO 1997017085 A3 WO1997017085 A3 WO 1997017085A3 US 9617860 W US9617860 W US 9617860W WO 9717085 A3 WO9717085 A3 WO 9717085A3
Authority
WO
WIPO (PCT)
Prior art keywords
casein
recombinant human
phosphorylated recombinant
influenzae
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/017860
Other languages
English (en)
Other versions
WO1997017085A9 (fr
WO1997017085A2 (fr
Inventor
Pradip Mukerji
Jennifer M Thurmond
Lennart Hansson
Jeffrey H Baxter
Robert G Hards
Amanda Eun-Yeong Leonard
Steven N Anderson
Linda A Harvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002234664A priority Critical patent/CA2234664A1/fr
Priority to EP96938817A priority patent/EP0862450A2/fr
Priority to AU76104/96A priority patent/AU7610496A/en
Priority to NZ322369A priority patent/NZ322369A/xx
Priority to JP9518321A priority patent/JP2000500141A/ja
Publication of WO1997017085A2 publication Critical patent/WO1997017085A2/fr
Publication of WO1997017085A9 publication Critical patent/WO1997017085A9/fr
Publication of WO1997017085A3 publication Critical patent/WO1997017085A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé permettant d'inhiber la fixation de H. influenzae sur des cellules humaines, telles que les cellules pharyngées, consistant à mettre le bacille en contact avec de la β-caséine humaine phosphorylée de recombinaison possédant au moins 3 groupes phosphate. Le produit contenant de la β-caséine humaine phosphorylée de recombinaison peut être un produit nutritionnel entéral liquide tel que du lait maternisé. Ledit produit nutritionnel entéral peut être utilisé pour prévenir et traiter l'otite moyenne chez les nourrissons. La β-caséine humaine phosphorylée de recombinaison peut également être administrée sous forme d'aérosol pour la gorge ou utilisée dans des gouttes ou des aérosols pour le nez.
PCT/US1996/017860 1995-11-06 1996-11-06 Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison Ceased WO1997017085A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002234664A CA2234664A1 (fr) 1995-11-06 1996-11-06 Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
EP96938817A EP0862450A2 (fr) 1995-11-06 1996-11-06 Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
AU76104/96A AU7610496A (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
NZ322369A NZ322369A (en) 1995-11-06 1996-11-06 Use of phosphorylated BETA H.influenzae
JP9518321A JP2000500141A (ja) 1995-11-06 1996-11-06 リン酸化された組換えヒトベータ−カゼインを用いるヒト細胞に対するインフルエンザ菌の付着阻止方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55252995A 1995-11-06 1995-11-06
US08/552,529 1995-11-06

Publications (3)

Publication Number Publication Date
WO1997017085A2 WO1997017085A2 (fr) 1997-05-15
WO1997017085A9 WO1997017085A9 (fr) 1997-06-26
WO1997017085A3 true WO1997017085A3 (fr) 1997-08-07

Family

ID=24205731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017860 Ceased WO1997017085A2 (fr) 1995-11-06 1996-11-06 Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison

Country Status (6)

Country Link
EP (1) EP0862450A2 (fr)
JP (1) JP2000500141A (fr)
AU (1) AU7610496A (fr)
MX (1) MX9803565A (fr)
NZ (1) NZ322369A (fr)
WO (1) WO1997017085A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
JP2000503319A (ja) * 1995-11-06 2000-03-21 アボツト・ラボラトリーズ インフルエンザ菌のヒト細胞への付着を防止するための生成物
US7982008B2 (en) 2002-11-27 2011-07-19 David Bar-Or Treatment of diseases and conditions mediated by increased phosphorylation
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (fr) * 1989-10-30 1991-05-16 Bengt Andersson Fraction de caseine a usage therapeutique, prophylactique et/ou diagnostique dans des infections des voies respiratoires
WO1991008675A1 (fr) * 1989-12-20 1991-06-27 Slattery Charles W Formules pour enfants contenant de l'alpha-lactalbumine et de la beta-caseine humaines recombinees
WO1993004171A1 (fr) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Beta-caseine humaine, procede de preparation et utilisation
WO1994006306A1 (fr) * 1992-09-22 1994-03-31 New Zealand Dairy Board Procede de preparation de produits enrichis en beta-caseine
WO1995032728A1 (fr) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition de la fixation de h. influenzae sur des cellules humaines
WO1995032727A1 (fr) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition de l'infection de cellules de mammiferes par le virus respiratoire syncytial
WO1996027018A1 (fr) * 1995-02-27 1996-09-06 Abbott Laboratories Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
JP2000503319A (ja) * 1995-11-06 2000-03-21 アボツト・ラボラトリーズ インフルエンザ菌のヒト細胞への付着を防止するための生成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (fr) * 1989-10-30 1991-05-16 Bengt Andersson Fraction de caseine a usage therapeutique, prophylactique et/ou diagnostique dans des infections des voies respiratoires
WO1991008675A1 (fr) * 1989-12-20 1991-06-27 Slattery Charles W Formules pour enfants contenant de l'alpha-lactalbumine et de la beta-caseine humaines recombinees
WO1993004171A1 (fr) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Beta-caseine humaine, procede de preparation et utilisation
WO1993004172A2 (fr) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Gene codant une beta-caseine humaine, procede d'obtention de la proteine et son utilisation dans une formulation a usage pediatrique
WO1994006306A1 (fr) * 1992-09-22 1994-03-31 New Zealand Dairy Board Procede de preparation de produits enrichis en beta-caseine
WO1995032728A1 (fr) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition de la fixation de h. influenzae sur des cellules humaines
WO1995032727A1 (fr) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition de l'infection de cellules de mammiferes par le virus respiratoire syncytial
WO1996027018A1 (fr) * 1995-02-27 1996-09-06 Abbott Laboratories Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.SVANBORG ET AL.: "ANTI-ADHESIVE MOLECULES IN HUMAN MILK", ADV.EXP.MED.BIOL., vol. 310, 1991, pages 167 - 171, XP000674221 *
G.ANIANSSON ET AL.: "Anti-adhesive activity of human casein against Streptococcus pneumoniae and Haemophilus influenzae", MICROB.PATHOG., vol. 8, no. 5, May 1990 (1990-05-01), pages 315 - 323, XP000674222 *

Also Published As

Publication number Publication date
NZ322369A (en) 1999-11-29
MX9803565A (es) 1998-09-30
WO1997017085A2 (fr) 1997-05-15
EP0862450A2 (fr) 1998-09-09
AU7610496A (en) 1997-05-29
JP2000500141A (ja) 2000-01-11

Similar Documents

Publication Publication Date Title
DE60014868T2 (de) Organspezifische Ernährung
NZ333695A (en) Method for treating gastrointestinal damage with hyperimmunised milk and hyperimmunised egg
CA2054358A1 (fr) Formulations nutritives tres acides
CA2143420A1 (fr) Aliments medicinaux pour le soutien nutritionnel dans les cas de maladies metaboliques chez le nourrisson et le jeune enfant
CA2137237A1 (fr) Formes purifiees de dnase
AU688803B2 (en) Method for treatment for pulmonary disease
EP0570791A3 (fr) Formule entérale pauvre en calories pour diminuer la diarrhée chez les patients alimentés par tube.
DE69123278D1 (de) Verwendung von kurzkettige Fettsäuren enthaltenden Lipiden zur Aufrechterhaltung der Integrität und der Funktion des Magen-Darm-Kanals
WO1997017085A3 (fr) Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
Larson et al. Frequency of eating as a factor in experimental dental caries
JPS57206608A (en) Production of gamma-globulin for intravenous injection
WO1997026320A3 (fr) Produit servant a inhiber la fixation de h. influenzae sur des cellules humaines
BE903829A (fr) Compositions dietetiques et leur preparation.
GB8402573D0 (en) Oral formulation
EP0409559A3 (en) Pharmaceutical and dietary uses of fatty acids
GR3031086T3 (en) Enantiomerically-enhanced nutritional energy substrates
MY132751A (en) Pogostemon cablin extract for inhibiting h. influenzae adhesion and treating otitis media or sore throat
FR2618305B1 (fr) Melange nutritif destine a la personne agee
HU9201412D0 (en) Process for the enzymatic hydrolysis of carbonic acid derivatives
MX9605829A (es) Inhibicion de la union del h. influenzae a celulas humanas.
Shaw The role of sugar in the aetiology of dental caries: 6. Evidence from experimental animal research
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
MX9605830A (es) Inhibicion de la infeccion de las celulas de mamiferos por el virus sincicial respiratorio.
Leung et al. The calcium absorption of Chinese children in relation to their intake
JPS57189637A (en) Production of acidic dairy beverage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-32,DESCRIPTION,REPLACED BY NEW PAGES 1-35;PAGES 33-35,CLAIMS,REPLACED BY NEW PAGES 36-39;PAGES 1/11-11/11,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 322369

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 518321

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2234664

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2234664

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003565

Country of ref document: MX

Ref document number: 1996938817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996938817

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996938817

Country of ref document: EP